The totality of evidence (to date) suggests that the muscle loss on GLP1 agonist drugs matches the muscle loss on an equivalent calorie restriction diet.
The muscle loss appears to come mainly from restricting calories— not from a side effect of the drug itself.
Meta-analysis of 22 RCT’s of GLP1 agonist drugs (Karakasis 2024) demonstrates loss of lean mass around 25% of total weight loss, which matches meta-analyses of diet trials (Heymsfield 2014) and bariatric surgery (Dubin 2024).
My note:
While increasing protein consumption on a GLP1 drug may help preserve muscle loss, there might be tradeoffs. In calorie restricted mice, increasing protein consumption attenuates the benefits of the calorie restriction. For example, the higher protein mice experience less beneficial autophagy. They do not live as long as the calorie restricted mice consuming a normal proportion of protein. How this tradeoff applies to humans is still unknown.










